Gelesis Holdings Revenue 2021-2022 | GLS

Gelesis Holdings revenue from 2021 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Gelesis Holdings Annual Revenue
(Millions of US $)
2021 $
2020 $
2019 $
Gelesis Holdings Quarterly Revenue
(Millions of US $)
2022-03-31 $8
2021-12-31
2021-09-30
2021-06-30
2021-03-31 $3
2020-12-31
2020-09-30
2020-06-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.111B $0.011B
Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Gelesis, formerly known as Capstar Special Purpose Acquisition Corp., is based in BOSTON.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $167.557B 10.19
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.634B 16.78
Biohaven Pharmaceutical Holding (BHVN) United States $10.186B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.637B 0.00
Arcus Biosciences (RCUS) United States $1.751B 44.40
Emergent Biosolutions (EBS) United States $1.570B 6.72
Myovant Sciences (MYOV) United Kingdom $1.212B 0.00
Zymeworks (ZYME) Canada $0.325B 0.00
Ambrx Biopharma (AMAM) United States $0.102B 0.00
Enzo Biochem (ENZ) United States $0.097B 0.00
SQZ Biotechnologies (SQZ) United States $0.091B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00